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Variation in the use of chemotherapy in lung cancer
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Factors influencing the use of chemotherapy for the initial (6 months) treatment of lung cancer in South East England were
investigated. The variables explored as possibly influencing the use of chemotherapy were sex, age, the year of diagnosis, the type of
lung cancer, the stage, the index of multiple deprivation and the cancer network of residence. w2 analysis and multivariate logistic
regression models were used to examine the effect of each of the variables on the use of chemotherapy. The results showed a highly
significant trend in use of chemotherapy over time; the adjusted proportion of patients receiving chemotherapy increasing from
13.6% in 1994 to 29.3% in 2003. However, age, cancer network and type of lung cancer had the strongest influence on the use of
chemotherapy. This finding is important when we consider that the NHS Cancer Plan aims at improving inequalities in cancer care in
the UK.
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Cancer is a major problem in the UK and inequalities in cancer
care have received much media interest. In 1995, the UK
Department of Health recommended a national framework for
cancer services in the UK (DoH, 1995). The NHS Plan (DoH,
2000a) presented the government’s strategy for investment and
reform across the NHS, and gave cancer services a high priority.
From this, the Cancer Plan (DoH, 2000b) was published, which set
out a comprehensive strategy for development of cancer care and
cancer services. One of the objectives is to reduce the incidence of
lung cancer and a number of objectives have been proposed to
ensure improved survival from the disease. Smoking, which is the
single most common cause of lung cancer and is responsible for
the disease occurrence (80–90% cases) (Doll et al, 1994; Peto et al,
2000), is highest on the agenda with an aim to reduce smoking
prevalence from 32% in 1998 to 26% by 2010. The Cancer Plan has
also set the target that by 2010, the 5-year survival for all cancers
will compare with the highest in Europe (DoH, 2000b).
Lung cancer is a common cause of death in the Western world
with 178 000 deaths in the US in 2002 and 38 000 in the UK per year
(NICE, 2005). For clinical, therapeutic and biological reasons, lung
cancers are frequently classified into small cell (SCLC) and non-
small cell (NSCLC). Non-small-cell lung cancer accounts for 80%
of all lung cancers and can be further divided into squamous
carcinoma, large-cell carcinoma and adenocarcinoma (including
bronchioloalveolar). Commonly, these subdivisions are grouped
together because approach to the diagnosis, staging, prognosis and
treatment are similar (Mason, 2005).
Treatment options for lung cancer include surgery, chemother-
apy and radiotherapy and depend on stage and performance status
of the patient. For NSCLC, the majority of patients are diagnosed
with advanced stage (IIIB and IV) and treatment (nonsurgical) is
predominantly palliative. In recent years, adjuvant chemotherapy
has been introduced following surgery for stage IB-IIIA. Although
chemotherapy has been established as treatment for SCLC since
the 1980s (Murray, 1997; Todd, 2005), chemotherapy for NSCLC
has only been supported by clinical studies in the past 10 years
(Spiro and Silvestre, 2005). Guidelines for treatment of lung cancer
have been published by the National Institute of Clinical
Excellence (NICE) in 2005 and by the American Society of Clinical
Oncology in 1999 with an update in 2003. Both guidelines
recommend chemotherapy for advanced stage patients (stage III
and IV NSCLC) in good performance.
The aim of this work was to explore variations and trends in the
use of chemotherapy as initial treatment in lung cancer. The two
main types of lung cancer are distinguished in this study but no
distinctions are made between the different types of chemotherapy.
We have limited our selection of explanatory variables to those
thought most pertinent and routinely collected by the Thames
Cancer Registry (TCR).
MATERIALS AND METHODS
The Thames Cancer Registry is the largest population based cancer
registry in Europe. In the period up to 2005, it covered a
population of over 14 million people in the South East of England,
comprising London, Essex, Sussex, Surrey, Kent and Hertford-
shire. The TCR obtains its data from a wide range of sources,
including pathology reports and case notes from NHS Trusts and
other medical institutions, the Office for National Statistics (ONS),
and from other cancer registries. The data for this analysis were
extracted from the TCR for 67 312 patients diagnosed with lung
Received 6 October 2006; revised 25 January 2007; accepted 29 January
2007; published online 6 March 2007
*Correspondence: Dr N Patel; E-mail: nilesh.patel@kcl.ac.uk
British Journal of Cancer (2007) 96, 886 – 890
& 2007 Cancer Research UK All rights reserved 0007 – 0920/07 $30.00
www.bjcancer.com
C
lin
ic
a
l
S
tu
d
ie
s
cancer between 1994 and 2003, who were not registered by death
certificate only. Of these patients, 11 215 received chemotherapy
within 6 months of diagnosis. This is the period in which routine
cancer registration collects treatment information. Explanatory
factors examined were the sex of the patient, age of the patient,
year of diagnosis, type of lung cancer, cancer stage, index of
multiple deprivation (IMD) and the cancer network in which the
patient was resident.
The IMD was assessed on the basis of postcode of residence and
classified into quintiles (most affluent ranked as 1, and the least
affluent ranked as 5). The IMD is based on certain domains of
deprivation, each made of certain indicators to cover all aspects of
socio-economic deprivation comprehensively.
Lung cancer type was differentiated as NSCLC, SCLC and NOS
(cancer not otherwise specified). The staging of NSCLC was based
on the TNM system, which was simplified in this study into stages
I to IV as reported in NICE guidelines (2005). SCLC staging
classification is defined as limited stage disease and extensive stage
disease and is not reported in this study. Patients were assigned
to a cancer network of residence based on their postcode at the
time of diagnosis. We report both the unadjusted and adjusted
proportions of patients who have received chemotherapy within
the first 6 months of diagnosis.
STATA (v.8.2) software was used for all statistical calculations.
Univariate comparisons were carried out using w2 analysis. On the
basis of the explanatory variables, multivariate logistic regression
models were used to examine the likelihood that each of the
variables had an effect on the patients subsequently receiving
chemotherapy. For each variable, the proportions were adjusted to
allow for differences in all of the other factors. P-values for trend
or for heterogeneity were computed as appropriate.
RESULTS
Table 1 shows the results of the logistic regression analysis. Both
unadjusted and adjusted proportions for the different factors
tested for patients receiving chemotherapy are shown. There was a
highly significant trend in use of chemotherapy and age. There
were a greater proportion of patients receiving chemotherapy in
the younger age groups and this trend was not sensitive to
statistical adjustment for other factors. The dependence on age was
present within individual strata of other variables, for example,
cancer network.
A comparison between male and female subjects showed no
significant difference between the initiation of chemotherapy (16.7
and 16.6%, respectively). After adjusting for the other factors, male
subjects (16.7%) were more likely than female subjects (15.4%) to
receive chemotherapy.
There was a significant trend with IMD. A greater proportion of
patients in the least deprived group (quintile 1) received
chemotherapy. After having adjusted for the other variables, the
trend became more pronounced and highly statistically significant.
Figure 1 shows the percentage of patients receiving chemother-
apy based on cancer type. There were a greater proportion of
patients with SCLC being treated with chemotherapy.
Figure 2 shows that there was a significantly increasing trend
in the proportion of patients receiving chemotherapy over the
10-year period. The proportion of patients receiving chemotherapy
increased constantly over time from 13.6% in 1994 to 21.2% in
2003 (unadjusted proportions). In the adjusted model, the gradient
became even steeper.
Figure 3 shows that over the 10-year period there was an
increase in the proportion of patients receiving chemotherapy who
have NSCLC from 7.2% in 1994 to 22.8% in 2003 (unadjusted
proportions). The trend does not seem to change over time in
chemotherapy use in patients with SCLC (variation between 51.3
and 58.4%).
A significant difference was seen in the proportion of patients
receiving chemotherapy in the different cancer networks ranging
from 8 to 24% (Figure 4). For patients with NSCLC, the variation
in chemotherapy use across the cancer networks was between 4.4
and 23.2%. For patients with SCLC, this variation across cancer
networks was between 35.8 and 64.7% (data not shown). The
overall lowest use of chemotherapy for both cancer types was
network K. Representation of the cancer networks is shown by
letters (A to M) to ensure anonymity.
There was an association between the stage of the cancer and use
of chemotherapy. The highest proportion of chemotherapy use was
in patients with stage III cancer, although there was no significant
difference (adjusted proportion) between patients with stages II,
III and IV receiving chemotherapy. However, after adjustment for
other factors, stage II patients were more likely to be initiated with
chemotherapy.
DISCUSSION
Chemotherapy is a systemic form of cytotoxic therapy, indicated
for both NSCLC and SCLC, and can be used in combination with
radiotherapy and surgery. Radical surgery is only available for
patients with early stage NSCLC, leaving palliative forms of
treatment to manage and reduce symptoms, help improve quality
of life and in some cases extend life expectancy (Jaklitsch et al,
2003; Todd, 2005). The choice of treatment is dependent on the
type of cancer, health status and co-morbidity of the patient. The
most important factors to consider regarding choosing chemother-
apy are the side effect profiles of the medication, use of concurrent
radiotherapy, performance status of the patient, patient and carrier
preference, and total cost difference between the various
chemotherapy regimens. When taking into account the perfor-
mance status of the patient the stage, type of cancer, age and co-
morbidity of the patient become important.
By far, the strongest determinant of use of chemotherapy
appears to be age, and this effect is remarkably insensitive to
statistical adjustment for type of cancer or stage. In general, the
highest proportion of patients suffering from lung cancer are over
the age of 65 (ONS, 2001; Spiro and Silvestre, 2005). The choice
of management must be individually considered and should be
based on the stage of the cancer, clinical and functional status,
concomitant disease, nutritional status and cognitive function. The
patient’s age should not be a contraindication for the commence-
ment of treatment. Shepherd et al (1994) came to a similar
conclusion when they looked at chemotherapy in elderly patients
in North America. However, it is appreciated in this study that age
is associated with other co-morbid conditions, and performance
status, which may contraindicate chemotherapy and it remains to
be determined if the apparent age effect is independent of these
factors. It is acknowledged that performance status is the most
important factor in determining chemotherapy, and it is likely that
most randomised trials have not included patients because of poor
performance status. However, no information about performance
status was available and, therefore, we can only speculate. It still
remains a possibility that the use of chemotherapy in older
patients is below the optimal level and that increased use of
chemotherapy in these patients could increase survival and quality
of life.
In this study, stage influenced the use of chemotherapy in
NSCLC, with patients having stage II cancer being more likely
to receive treatment compared to those with stage IV. In the case of
stage IIIB or IV NSCLC, which is generally not considered curable,
with 5-year survival rates of less than 1%, chemotherapy options
are limited. However, more recently, newer drugs and regimens
have been found to combat more aggressive forms of cancer, the
importance of which is limited by our study design. It is also
known that targeting therapy at an early stage of cancer increases
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Table 1 Number, unadjusted and adjusted proportions of patients receiving chemotherapy within 6 months of diagnosis, by various factors
No. of patients receiving CT Total no. of patients Unadjusted proportion (%) Adjusted proportion (%)
Age group
0–40 471 1092 43.1 43.1
45 645 1566 41.2 38.3
50 1126 2987 37.7 33.2
55 1542 4819 32.0 26.6
60 1847 6996 26.4 20.9
65 2140 10 290 20.8 16.6
70 1901 13 203 14.4 10.9
75 1163 12 627 9.2 6.6
80–100 382 13 732 2.8 2.1
Test for trend w2¼ 5289.6 (Po0.001) w2¼ 4602.7 (Po0.001)
Sex
Male 6958 41 667 16.7 16.7
Female 4257 25 645 16.6 15.4
Test for heterogeneity w2¼ 0.12 (P¼ 0.7309) w2¼ 13.36 (P¼ 0.003)
IMD quintile
1 Least deprived 1734 9,999 18.3 18.3
2 2025 11 595 17.0 15.7
3 2486 13 099 15.9 14.5
4 2325 15 225 15.5 12.8
5 Most deprived 2646 17 394 17.4 12.8
Test for trend w2¼ 6.51 (P¼ 0.0107) w2¼ 103.2 (Po0.001)
Cancer type
NSCLC 4332 31 977 13.5 13.5
SCLC 4648 8668 53.6 60.7
NOS 2236 26 667 8.4 10.0
Test for heterogeneity w2¼ 9519.1 (Po0.001) w2¼ 7394.3 (Po0.001)
Year of diagnosis
1994 830 6116 13.6 13.6
1995 832 6352 13.1 13.8
1996 939 6266 15.0 16.0
1997 968 6543 14.8 16.7
1998 1065 7010 15.2 17.8
1999 1115 6915 16.1 19.2
2000 1319 7305 18.1 22.6
2001 1330 7072 18.8 24.6
2002 1392 6994 19.9 26.6
2003 1426 6739 21.2 29.3
Test for trend w2¼ 306.5 (Po0.001) w2¼ 672.2 (Po0.001)
Cancer network
A 1466 8163 18.0 18.0
B 1414 7755 18.2 20.5
C 1155 6208 18.6 20.7
D 1377 7895 17.4 18.6
E 725 3902 18.6 20.5
F 1405 5839 24.1 27.7
G 972 5591 17.4 16.6
H 641 5912 10.8 10.3
I 115 1110 10.4 10.9
J 511 2833 18.0 16.9
K 354 4560 7.8 6.1
L 73 486 15.0 12.6
M 1008 7058 14.3 14.2
Test for heterogeneity w2¼ 762.7 (Po0.001) w2¼ 927.5 (Po0.001)
Stage
I 3173 21 620 14.7 14.7
II 642 3095 20.7 19.2
III 425 2031 20.9 15.5
IV 4448 21 668 20.5 15.7
Not known 2528 18 898 13.4 13.5
Test for trend w2¼ 243.4 (Po0.001) w2¼ 5.0 (P¼ 0.0255)
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the chance of eradicating the cancer and prolonging life. The fact
that chemotherapy is introduced early may indicate improvements
in lung cancer diagnosis and detection.
NICE recommends the routine use of chemotherapy in SCLC
(NICE, 2001a). Chemotherapy in SCLC provides a more favourable
outcome in patients with disease confined to the chest, minimal
weight loss and good performance status. For patients with
NSCLC, chemotherapy is recommended as adjuvant therapy and
for the palliative treatment of advanced NSCLC. In this study, a
greater proportion of patients with SCLC were shown to receive
chemotherapy compared to patients with NSCLC and NOS. This
result suggests some concordance with national guidelines, but the
overall proportion of patients receiving chemotherapy remains
low (only 60%) despite the aggressiveness of SCLC. A US study of
limited disease SCLC found that approximately 70% of patients
received chemotherapy or chemoradiotherapy (Gaspar et al 2005).
Differences in the numbers of SCLC patients receiving chemother-
apy in the UK compared to countries such as North America and
Japan may reflect differences in the choice of drugs used, previous
low success rates of treatment with older drugs and selection
criteria based on performance. Also, the role of surgery continues
to be explored, more in Europe than in North America or Asia
(Turrisi and Sherman, 2002). A Swedish study found that 38% of
patients did not receive lung cancer specific treatment (Myrdal
et al, 2004). However, it is not uncommon for patients to reject the
option of chemotherapy for advanced stages of lung cancer. It was
estimated that in 2001, only 5–20% of patients received palliative
chemotherapy (NICE, 2001b).
The proportion of patients receiving chemotherapy increased
year-on-year from 1994 to 2003. For patients with NSCLC there has
been a gradual increase in chemotherapy use, whereas for those
patients with SCLC, where treatments have been established for
many years, the overall use has not increased. Contributing to the
overall increase in chemotherapy with time are better detection of
lung cancer, increased effectiveness of chemotherapeutic regimens
with lower side effect profiles, and use of chemotherapy in
combined modalities, meaning more patients have chemotherapy
indicated as part of their therapy. The greater acceleration seen in
use of chemotherapy after the year 2000 may be related to the
release of The NHS Cancer Plan in 2000, and subsequent release of
NICE guidelines. However, the actual impact of the increase in
cancer care and services since the introduction of the guidelines
has yet to be determined.
Across England, cancer networks provide the operational model
for cancer services. Each cancer network is responsible for the
delivery of all cancer services within a geographical area. There are
34 cancer networks spread geographically throughout the country,
and these were commissioned after the publication of the Calmine-
Hime report in April 1995 (Munro, 2001). However, there is
considerable variation between the cancer networks in their use
of chemotherapy for lung cancer. Further analysis in the use of
chemotherapy in patients with NSCLC and SCLC showed
variations in use across the cancer networks (data not shown). It
is interesting to note that variations in chemotherapy use in
patients with SCLC across the cancer networks exist especially
since this is a strong indication for chemotherapy and established
treatments have existed for many years. For patients with NSCLC
the variations in chemotherapy use across cancer networks, and
with time, are large and as yet unexplained. Noteworthy is that the
chance of having an approved treatment for lung cancer is not the
same. For SCLC the difference is twofold and for NSCLC it is
fivefold. This difference may reflect a reluctance in certain cancer
networks towards offering treatment to a particular group of
cancer patients. It would be interesting to extend this study to see
if the same differences in chemotherapy use across networks over
time were found in breast cancer, which has a longer tradition for
chemotherapy use.
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Figure 1 Percentage of patients receiving chemotherapy according to
the type of lung cancer. NSCLC denotes non-small-cell lung cancer; SCLC
denotes small-cell-lung cancer; NOS denotes cancer not otherwise
specified.
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Figure 2 Percentage of patients receiving chemotherapy according to
the year of diagnosis.
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Figure 3 Unadjusted proportions of NSCLC and SCLC patients
receiving chemotherapy by year of diagnosis. NSCLC denotes non-small-
cell lung cancer; SCLC denotes small-cell-lung cancer
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Figure 4 Percentage of patients receiving chemotherapy according to
cancer network.
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Additionally, variations between cancer networks may be driven
by disparity in financial resources available for chemotherapeutic
services or it may be due to variation in established or informal
patterns of clinical practice in hospitals and cancer networks.
Unfortunately, there are considerable differences with respect to
data capture, availability, accuracy and completeness of the data
from the individual networks. The variation between cancer
networks may in part reflect artefactual differences in data
availability, but this is unlikely to account for a large part of the
observed variation. It may be that the low use of chemotherapy in
some of the networks suggests that these networks may simply be
slow in implementing new treatments. If this is the case, then the
differences cannot be explained by differences in patients, but
rather in the knowledge of the treating physicians. Also, in the
particular case of cancer network I, the Thames Cancer Registry
covers only a small part, and it is likely that we have missed a
proportion of chemotherapy episodes which took place in the part
of this network which is covered by the adjacent cancer registry.
We are not aware of any other obvious sources of artefactual
variation between the cancer networks that would importantly
influence the interpretation of the data.
Socio-economic factors have been identified as an important
determinant of access to cancer services, with the less affluent
populations having poorer access to specialist services and
treatments. This inequality is commonly referred to as the
‘postcode lottery’ (Coleman et al, 2004; Bungay, 2005). The NHS
Cancer Plan has recognised this inequality and has proposed
methods of reducing these inequalities by improving access for the
poor to specialist services and more importantly providing a
comprehensive programme of guidance setting national standards.
However, Coleman et al (2004) have shown that the poverty gap in
cancer survival has widened in England and Wales. There may be
many reasons for this variation, including diet, smoking and other
lifestyle habits among the poor, as well as access to appropriately
trained health personnel and therapy. While our data suggest a
statistically significant gradient in the direction of more frequent
use of chemotherapy in the highest socio-economic groups, the
absolute differences are very small in comparison with the
variations between age-groups or between cancer networks.
Interestingly, studies in the USA by Earle et al (2002) and
Greenberg et al (1988a, b) into the variation in use of palliative
chemotherapy for advanced non-small-cell lung cancer showed no
relationship with race, socio-economic class and geographic
location once referral by an oncologist was made.
All the factors considered in this study contributed to a different
extent to those patients who received chemotherapy or not. It is
interesting to note the reports in the media profiling patients who
do not receive chemotherapy as a result of cost. Cost of
chemotherapy in lung cancer patients can be considerable, and if
NICE guidelines are followed with use of new generation and more
expensive drugs, the impact on whether patients receive che-
motherapy may widen the gaps already seen in cancer treatment
within the NHS. By many accounts, the inequalities seen in cancer
care and choice of drugs are still present and it may yet be too
early to determine if the Cancer Plan is fulfilling all its objectives.
In the case of lung cancer, use of chemotherapy is improving but
advancements are needed in education and funding as these will
have an impact on choice of therapy. Additionally, observations in
to the use of chemotherapy for other cancers and across different
regions and countries warrants further consideration.
Conflict of interest statement
None of the authors have any financial or personal relationships
with other people or organisations that could inappropriately
influence (bias) our work.
REFERENCES
Bungay H (2005) Cancer and Health Policy: the postcode lottery of care. Soc
Policy Admini 39: 35 – 48
Coleman MP, Rachet B, Woods LM, Mitry E, Riga M, Cooper N, Quinn MJ,
Brenner H, Este’ve J (2004) Trends and socioeconomic equalities in cancer
survival in England and Wales up to 2001. Br J Cancer 90: 1367 – 1373
Department of Health (DoH) (1995) A policy framework for commissioning
cancer services: A report by the Expert Advisory Group on cancer to the Chief
Medical Officers of England and Wales. London: Department of Health
Department of Health (DoH) (2000a) The NHS Plan. London: Department
of Health
Department of Health (DoH) (2000b) The Cancer Plan. London: Depart-
ment of Health
Doll R, Peto R, Wheatley K, Gray R, Sutherland I (1994) Mortality in
relation to smoking: 40 years’ observation on male British doctors. BMJ
309: 901 – 911
Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks JC (2002) Impact
of referral patterns on the use of chemotherapy for lung cancer. J Clin
Oncol 20: 1786 – 1792
Gaspar LE, Gat EG, Crawford J, Putnam JB, Herbst RS, Bonner JA (2005)
Limited-stage small-cell lung cancer (stages I-III): observations from the
National Cancer Database. Clin Lung Cancer 6: 355 – 360
Greenberg ER, Chute CG, Stukel T, Baron JA, Freeman DH, Yates J, Korson
R (1988a) Social and economic factors in the choice of lung cancer
treatment: a population-based study in two rural states. N Eng J Med 318:
612 – 617
Greenberg ER, Dain B, Freeman D, Yates J, Korson R (1988b) Referral of
lung cancer patients to University hospital cancer centres: a population-
based study in two rural states. Cancer 62: 1647 – 1652
Jaklitsch MT, Mery CM, Audisio RA (2003) The use of surgery to treat lung
cancer in elderly patients. Lancet Oncol 4: 463 – 471
Mason P (2005) Lung cancer – the disease and non-drug treatment. Hosp
Pharmacist 12: 129 – 135
Munro AJ (2001) The Calman – Hine report: its causes and its con-
sequences. Eur J Cancer Care 10: 212 – 220
Murray N (1997) Treatment of small-cell lung cancer; the state of the art.
Lung Cancer 17: S75 – S90
Myrdal G, Lambe M, Hillerdal G, Lamberg K, Agustsson Th, Stahle E (2004)
Effects of delays on prognosis in patients with non-small cell lung cancer.
Thorax 59: 45 – 49
National Institute for Clinical Excellence (NICE) (2001a) Guidance on
drugs for lung cancer. Developed by the National Collaborating Centre
for Acute Care. Available at www.nice.org.uk/page.aspx?o¼ 26203
(accessed 26 February 2006)
National Institute for Clinical Excellence (NICE) (2001b) Guidance on use
of docetaxel, paclitaxel, gemticabine and vincrelbine for the treatment of
non-small cell lung cancer. Developed by the National Collaborating
Centre for Acute Care. Available at www.nice.org.uk/page.aspx?o¼ 17536
(accessed 26 February 2006)
National Institute for Clinical Excellence (NICE) (2005) Lung Cancer. The
diagnosis and treatment of lung cancer. Developed by the National
Collaborating Centre for Acute Care. Available at www.nice.org.uk/
CG024NICEguideline (accessed 26 February 2006)
Office for National Statistics (2001) Cancer Survival, England 1993 – 2000.
London: Office for National Statistics
Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R (2000) Smoking,
smoking cessation, and lung cancer in the UK since 1950: combination
of national statistics with two case – control studies. BMJ 321:
323 – 329
Shepherd FA, Amdemichael E, Evans WK, Chalvardjian P, Hoggjohnson S,
Coates R, Paul K (1994) Treatment of small cell lung cancer in the
elderly. JAGS 42: 64 – 70
Spiro SG, Silvestre GA (2005) The treatment of advanced non-small cell
lung cancer. Curr Opin Pulm Med 11: 287 – 291
Todd K (2005) Lung cancer – the role of chemotherapy. Hosp Pharmacist
12: 137 – 143
Turrisi AT, Sherman CA (2002) The treatment of limited small cell lung
cancer: a report of the progress made and future prospects. Eur J Cancer
38: 279 – 291
Chemotherapy use in lung cancer
N Patel et al
890
British Journal of Cancer (2007) 96(6), 886 – 890 & 2007 Cancer Research UK
C
lin
ic
a
l
S
tu
d
ie
s
